Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases. However, biologics are driving the rising cost of healthcare, and this may restrict access to life-saving treatment.
A biosimilar is an approved biological product with quality, safety and efficacy similar to those of an approved reference product. We invest in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics.
We are the pioneer and global leader in biosimilars with over a decade of experience.
Sandoz is committed to increasing patients' access to quality biosimilars that improve their quality of life. It is a pioneer and world leader in biosimilars and has three commercialized products: recombinant human growth hormone somatropin, recombinant human erythropoietin (epoetin alfa) and GCSF
With a leading portfolio of products under development, Sandoz intends to market by 2020, five biosimilars of the main biological products in immunology and oncology in key geographic areas. The portfolio of products in the initial development phase of Sandoz has additional assets in oncology, in addition to specialized therapeutic areas, and it is intended to start new programs
As a Novartis Division, Sandoz has a privilege position for leading the Biopharmaceuticals industry based on the experience and the development, manufacturing and commercialization capabilities.